eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
yesterday they welcomed the findings of coroner patrick mcgurgan, who criticised the staff caring for mrs cavanagh over a series of missed opportunities.
.
.
"if the battery in a mechanical mod over-discharges and the device doesn't contain enough air holes to allow the battery to vent, there is a risk of explosion."
.ai-based software may help predict risk of dementia
.
.
.